Demographic information for patients with stage III/IV ovarian cancer
| Parameter, n (%) | All patients with stage III/IV ovarian cancer (N=5386) |
| Histology | |
| High-grade serous carcinoma | 3249 (60.3) |
| High-grade endometrioid carcinoma | 372 (6.9) |
| Other* | 1765 (32.8) |
| BRCA | |
| BRCA mutation | 1427 (26.5) |
| BRCA wild-type | 3000 (55.7) |
| Not tested | 959 (17.8) |
| Homologous recombination deficiency | |
| Homologous recombination deficient | 217 (4.0) |
| Homologous recombination proficient | 926 (17.2) |
| Not tested | 4243 (78.8) |
| Homologous recombination repair | |
| Homologous recombination repair mutation | 146 (2.7) |
| Homologous recombination repair wild-type | 1479 (27.5) |
| Not tested | 3761 (69.8) |
| Tumor cytoreductive surgery | |
| Optimal tumor cytoreduction | 1236 (23.0) |
| Suboptimal, no surgery, or unknown | 4150 (77.0) |
| Response to initial treatment | |
| Complete response or partial response to initial treatment in patients receiving first-line maintenance | 1803 (33.5) |
| Stable disease or progressive disease to initial treatment in patients receiving first-line maintenance | 201 (3.7) |
| Unknown response to initial treatment in patients receiving first-line maintenance | 1012 (18.8) |
| Did not receive first-line maintenance | 2370 (44.0) |
*Other histologies include clear cell carcinoma, low-grade serous carcinoma, low-grade endometrioid carcinoma, mucinous carcinoma, seromucinous carcinoma, and malignant Brenner tumor.